{
    "title": "Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Securing Opioids and Unused \nNarcotics with Deliberate Disposal and Packaging Act of 2018'' or the \n``SOUND Disposal and Packaging Act''.\n\nSEC. 2. IMPROVED TECHNOLOGIES, CONTROLS, OR MEASURES WITH RESPECT TO \n              THE PACKAGING OR DISPOSAL OF CERTAIN DRUGS.\n\n    (a) In General.--Chapter V of the Federal Food, Drug, and Cosmetic \nAct is amended by inserting after section 505-1 (21 U.S.C. 355-1) the \nfollowing new section:\n\n``SEC. 505-2. SAFETY-ENHANCING PACKAGING AND DISPOSAL FEATURES.\n\n    ``(a) Orders.--\n            ``(1) In general.--The Secretary may issue an order \n        requiring the holder of a covered application to implement or \n        modify one or more technologies, controls, or measures with \n        respect to the packaging or disposal of one or more drugs \n        identified in the covered application, if the Secretary \n        determines such technologies, controls, or measures to be \n        appropriate to help mitigate the risk of abuse or misuse of \n        such drug or drugs, which may include by reducing the \n        availability of unused drugs.\n            ``(2) Prior consultation.--The Secretary may not issue an \n        order under paragraph (1) unless the Secretary has consulted \n        with relevant stakeholders, through a public meeting, workshop, \n        or otherwise, about matters that are relevant to the subject of \n        the order.\n            ``(3) Assuring access and minimizing burden.--Technologies, \n        controls, or measures required under paragraph (1) shall--\n                    ``(A) be commensurate with the specific risk of \n                abuse or misuse of the drug listed in the covered \n                application;\n                    ``(B) considering such risk, not be unduly \n                burdensome on patient access to the drug, considering \n                in particular any available evidence regarding the \n                expected or demonstrated public health impact of such \n                technologies, controls, or measures; and\n                    ``(C) reduce the risk of abuse or misuse of such \n                drug.\n            ``(4) Order contents.--An order issued under paragraph (1) \n        may--\n                    ``(A) provide for a range of options for \n                implementing or modifying the technologies, controls, \n                or measures required to be implemented by such order; \n                and\n                    ``(B) incorporate by reference standards regarding \n                packaging or disposal set forth in an official \n                compendium, established by a nationally or \n                internationally recognized standard development \n                organization, or described on the public website of the \n                Food and Drug Administration, so long as the order \n                includes the rationale for incorporation of such \n                standard.\n            ``(5) Orders applicable to drug class.--When a concern \n        about the risk of abuse or misuse of a drug relates to a \n        pharmacological class, the Secretary may, after consultation \n        with relevant stakeholders, issue an order under paragraph (1) \n        which applies to the pharmacological class.\n    ``(b) Compliance.--The holder of a covered application shall--\n            ``(1) submit a supplement containing proposed changes to \n        the covered application to comply with an order issued under \n        subsection (a) not later than--\n                    ``(A) 180 calendar days after the date on which the \n                order is issued; or\n                    ``(B)(i) such longer time period as specified by \n                the Secretary in such order; or\n                    ``(ii) if a request for an alternative date is \n                submitted by the holder of such application not later \n                than 60 calendar days after the date on which such \n                order is issued--\n                            ``(I) such requested alternative date if \n                        agreed to by the Secretary; or\n                            ``(II) another date as specified by the \n                        Secretary; and\n            ``(2) implement the changes approved pursuant to such \n        supplement not later than the later of--\n                    ``(A) 90 calendar days after the date on which the \n                supplement is approved; or\n                    ``(B) the end of such longer period as is--\n                            ``(i) determined to be appropriate by the \n                        Secretary; or\n                            ``(ii) approved by the Secretary pursuant \n                        to a request by the holder of the covered \n                        application that explains why such longer \n                        period is needed, including to satisfy any \n                        other applicable Federal statutory or \n                        regulatory requirements.\n    ``(c) Alternative Measures.--The holder of the covered application \nmay propose, and the Secretary shall approve, technologies, controls, \nor measures regarding packaging, storage, or disposal other than those \nspecified in the applicable order issued under subsection (a), if such \ntechnologies, controls, or measures are supported by data and \ninformation demonstrating that such alternative technologies, controls, \nor measures can be expected to mitigate the risk of abuse or misuse of \nthe drug or drugs involved, including by reducing the availability of \nunused drugs, to at least the same extent as the technologies, \ncontrols, or measures specified in such order.\n    ``(d) Dispute Resolution.--If a dispute arises in connection with a \nsupplement submitted under subsection (b), the holder of the covered \napplication may appeal a determination made with respect to such \nsupplement using applicable dispute resolution procedures specified by \nthe Secretary in regulations or guidance.\n    ``(e) Definitions.--In this section--\n            ``(1) the term `covered application' means an application \n        submitted under subsection (b) or (j) of section 505 for \n        approval under such section or an application submitted under \n        section 351 of Public Health Service Act for approval under \n        such section, with respect to a drug that is or contains an \n        opioid for which a listing in schedule II or III (on a \n        temporary or permanent basis) is in effect under section 202 of \n        the Controlled Substances Act; and\n            ``(2) the term `relevant stakeholders' may include \n        scientific experts within the drug manufacturing industry; \n        brand and generic drug manufacturers; standard development \n        organizations; wholesalers and distributors; payers; health \n        care providers; pharmacists; pharmacies; manufacturers; poison \n        centers; and representatives of the National Institute on Drug \n        Abuse, the National Institutes of Health, the Centers for \n        Disease Control and Prevention, the Centers for Medicare & \n        Medicaid Services, the Drug Enforcement Agency, the Consumer \n        Product Safety Commission, individuals who specialize in \n        treating addiction, and patient and caregiver groups.''.\n    (b) Prohibited Acts.--Section 501 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 351) is amended by inserting after paragraph \n(j) the following:\n    ``(k) If it is a drug approved under a covered application (as \ndefined in section 505-2(e)), the holder of which does not meet the \nrequirements of paragraphs (1) and (2) of subsection (b) of such \nsection.''.\n    (c) Required Content of an Abbreviated New Drug Application.--\nSection 505(j)(2)(A) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 355(j)(2)(A)) is amended--\n            (1) in clause (vii)(IV), by striking ``and'' at the end;\n            (2) in clause (viii), by striking the period at the end and \n        inserting ``; and''; and\n            (3) by adding at the end the following:\n            ``(ix) if the drug is or contains an opioid for which a \n        listing in schedule II or III (on a temporary or permanent \n        basis) is in effect under section 202 of the Controlled \n        Substances Act, information to show that the applicant has \n        proposed technologies, controls, or measures related to the \n        packaging or disposal of the drug that provide protections \n        comparable to those provided by the technologies, controls, or \n        measures required for the applicable listed drug under section \n        505-2, if applicable.''.\n    (d) Grounds for Refusing to Approve an Abbreviated New Drug \nApplication.--Section 505(j)(4) of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 355(j)(4)), is amended--\n            (1) in subparagraph (J), by striking ``or'' at the end;\n            (2) in subparagraph (K), by striking the period at the end \n        and inserting ``; or''; and\n            (3) by adding at the end the following:\n                    ``(L) if the drug is a drug described in paragraph \n                (2)(A)(ix) and the applicant has not proposed \n                technologies, controls, or measures related to the \n                packaging or disposal of such drug that the Secretary \n                determines provide protections comparable to those \n                provided by the technologies, controls, or measures \n                required for the applicable listed drug under section \n                505-2.''.\n    (e) Rules of Construction.--\n            (1) Any labeling describing technologies, controls, or \n        measures related to packaging or disposal intended to mitigate \n        the risk of abuse or misuse of a drug product that is subject \n        to an abbreviated new drug application, including labeling \n        describing differences from the reference listed drug resulting \n        from the application of section 505-2 of the Federal Food, \n        Drug, and Cosmetic Act, as added by subsection (a), shall not \n        be construed--\n                    (A) as changes to labeling not permissible under \n                clause (v) of section 505(j)(2)(A) of such Act (21 \n                U.S.C. 355(j)(2)(A)), or a change in the conditions of \n                use prescribed, recommended, or suggested in the \n                labeling proposed for the new drug under clause (i) of \n                such section; or\n                    (B) to preclude approval of an abbreviated new drug \n                application under subparagraph (B) or (G) of section \n                505(j)(4) of such Act (21 U.S.C. 355(j)(4)).\n            (2) For a covered application that is an application \n        submitted under subsection (j) of section 505 of the Federal \n        Food, Drug, and Cosmetic Act (21 U.S.C. 355), subsection \n        (j)(2)(A) of such section 505 shall not be construed to limit \n        the type of data or information the Secretary of Health and \n        Human Services may request or consider in connection with \n        making any determination under section 505-2.\n    (f) GAO Report.--Not later than 12 months after the date of \nenactment of this Act, the Comptroller General of the United States \nshall prepare and submit to the Congress a report containing--\n            (1) a description of available evidence, if any, on the \n        effectiveness of site-of-use, in-home controlled substance \n        disposal products and packaging technologies;\n            (2) identification of ways in which such disposal products \n        intended for use by patients, consumers, and other end users \n        that are not registrants under the Controlled Substances Act, \n        are made available to the public and barriers to the use of \n        such disposal products;\n            (3) identification of ways in which packaging technologies \n        are made available to the public and barriers to the use of \n        such technologies;\n            (4) a description of Federal oversight, if any, of site-of-\n        use, in-home controlled substance disposal products, \n        including--\n                    (A) identification of the Federal agencies that \n                oversee such products;\n                    (B) identification of the methods of disposal of \n                controlled substances recommended by these agencies for \n                site-of-use, in-home disposal; and\n                    (C) a description of the effectiveness of such \n                recommendations at preventing the diversion of legally \n                prescribed controlled substances;\n            (5) a description of Federal oversight, if any, of \n        controlled substance packaging technologies, including--\n                    (A) identification of the Federal agencies that \n                oversee such technologies;\n                    (B) identification of the technologies recommended \n                by these agencies, including unit dose packaging, \n                packaging that provides a set duration, or other \n                packaging systems that may mitigate abuse or misuse; \n                and\n                    (C) a description of the effectiveness of such \n                recommendations at preventing the diversion of legally \n                prescribed controlled substances; and\n            (6) recommendations on--\n                    (A) whether site-of-use, in-home controlled \n                substance disposal products and packaging technologies \n                require Federal oversight and, if so, which agencies \n                should be responsible for such oversight and, as \n                applicable, approval of such products or technologies; \n                and\n                    (B) the potential role of the Federal Government in \n                evaluating such products to ensure product efficacy.\n\n            Passed the House of Representatives June 19, 2018.\n\n            Attest:\n\n                                                 KAREN L. HAAS,\n\n                                                                 Clerk."
}